155 related articles for article (PubMed ID: 21057701)
1. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.
Wu CC; Wang WY; Wei CK; Teng CM
Thromb Haemost; 2011 Jan; 105(1):88-95. PubMed ID: 21057701
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
4. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
5. YD-3, a novel inhibitor of protease-induced platelet activation.
Wu CC; Huang SW; Hwang TL; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 2000 Jul; 130(6):1289-96. PubMed ID: 10903968
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
[TBL] [Abstract][Full Text] [Related]
8. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
9. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
10. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
11. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
12. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
[TBL] [Abstract][Full Text] [Related]
16. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
17. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II.
Monteiro RQ; Rapôso JG; Wisner A; Guimarães JA; Bon C; Zingali RB
Biochem Biophys Res Commun; 1999 Sep; 262(3):819-22. PubMed ID: 10471408
[TBL] [Abstract][Full Text] [Related]
18. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M
Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
